Optison imaging agent sales begin to take off
This article was originally published in Clinica
Clinical acceptance of Optison, the only FDA-approved gas-filled albumin bubble ultrasound contrast imaging agent, is beginning to grow, according to Molecular Biosystems, with end-user sales growing 25%, comparing the first quarter of 1999 with the last quarter of 1998. However, the San Diego, California-based company conceded that the increased end-user sales of the myocardial perfusion contrast imaging agent came from stock already purchased by its marketing partner, Mallinckrodt.
You may also be interested in...
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.